Virus-like particles presenting interleukin-33 molecules

References

• Grotenboer NS, Ketelaar ME, Koppelman GH, Nawijn MC. Decoding asthma: translating genetic variation in IL33 and IL1RL1 into disease pathophysiology. J Allergy Clin Immunol 2013; 131:856 - 65; http://dx.doi.org/10.1016/j.jaci.2012.11.028; PMID: 23380221
   PubMed Web of Science ®Google Scholar
• Préfontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, Lemière C, Martin JG, Hamid Q. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009; 183:5094 - 103; http://dx.doi.org/10.4049/jimmunol.0802387; PMID: 19801525
   PubMed Web of Science ®Google Scholar
• Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, Hoshino T, Fujimoto J, Nakanishi K. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008; 20:791 - 800; http://dx.doi.org/10.1093/intimm/dxn037; PMID: 18448455
   PubMed Web of Science ®Google Scholar
• Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol 2010; 185:3472 - 80; http://dx.doi.org/10.4049/jimmunol.1000730; PMID: 20693421
   PubMed Web of Science ®Google Scholar
• Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S, Pitman N, Mirchandani A, Rana B, van Rooijen N, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009; 183:6469 - 77; http://dx.doi.org/10.4049/jimmunol.0901575; PMID: 19841166
   PubMed Web of Science ®Google Scholar
• Barlow JL, Peel S, Fox J, Panova V, Hardman CS, Camelo A, Bucks C, Wu X, Kane CM, Neill DR, et al. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J Allergy Clin Immunol 2013; 132:933 - 41; http://dx.doi.org/10.1016/j.jaci.2013.05.012; PMID: 23810766
   PubMed Web of Science ®Google Scholar
• Yin H, Li XY, Liu T, Yuan BH, Zhang BB, Hu SL, Gu HB, Jin XB, Zhu JY. Adenovirus-mediated delivery of soluble ST2 attenuates ovalbumin-induced allergic asthma in mice. Clin Exp Immunol 2012; 170:1 - 9; http://dx.doi.org/10.1111/j.1365-2249.2012.04629.x; PMID: 22943195
   PubMed Web of Science ®Google Scholar
• Mizutani N, Nabe T, Yoshino S. Interleukin-33 and alveolar macrophages contribute to the mechanisms underlying the exacerbation of IgE-mediated airway inflammation and remodelling in mice. Immunology 2013; 139:205 - 18; http://dx.doi.org/10.1111/imm.12071; PMID: 23323935
   PubMed Web of Science ®Google Scholar
• Kim HY, Chang YJ, Subramanian S, Lee HH, Albacker LA, Matangkasombut P, Savage PB, McKenzie AN, Smith DE, Rottman JB, et al. Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J Allergy Clin Immunol 2012; 129:216 - 27, e1-6; http://dx.doi.org/10.1016/j.jaci.2011.10.036; PMID: 22119406
   PubMed Web of Science ®Google Scholar
• Saglani S, Lui S, Ullmann N, Campbell GA, Sherburn RT, Mathie SA, Denney L, Bossley CJ, Oates T, Walker SA, et al. IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. J Allergy Clin Immunol 2013; 132:676 - 85, e13; http://dx.doi.org/10.1016/j.jaci.2013.04.012; PMID: 23759184
   PubMed Web of Science ®Google Scholar
• Delavallée L, Duvallet E, Semerano L, Assier E, Boissier MC. Anti-cytokine vaccination in autoimmune diseases. Swiss Med Wkly 2010; 140:w13108; PMID: 21043003
   PubMedGoogle Scholar
• Lee CK, Kim HS, Ye BD, Lee KM, Kim YS, Rhee SY, Kim HJ, Yang SK, Moon W, Koo JS, et al, Korean Association for the Study of Intestinal Diseases (KASID) Study. Patients with Crohn’s disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis 2014; 8:384 - 91; http://dx.doi.org/10.1016/j.crohns.2013.09.022; PMID: 24144611
   PubMed Web of Science ®Google Scholar
• Ma Y, Halayko AJ, Basu S, Guan Q, Weiss CR, Ma AG, HayGlass KT, Becker AB, Warrington RJ, Peng Z. Sustained suppression of IL-13 by a vaccine attenuates airway inflammation and remodeling in mice. Am J Respir Cell Mol Biol 2013; 48:540 - 9; http://dx.doi.org/10.1165/rcmb.2012-0060OC; PMID: 23470628
   PubMed Web of Science ®Google Scholar
• Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, Jetten AM, Khoury SJ, Fuhlbrigge RC, Kuchroo VK, et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012; 18:1248 - 53; http://dx.doi.org/10.1038/nm.2856; PMID: 22772464
   PubMed Web of Science ®Google Scholar
• Guler R, Parihar SP, Spohn G, Johansen P, Brombacher F, Bachmann MF. Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine 2011; 29:1339 - 46; http://dx.doi.org/10.1016/j.vaccine.2010.10.045; PMID: 21093494
   PubMed Web of Science ®Google Scholar
• Guan Q, Weiss CR, Qing G, Ma Y, Peng Z. An IL-17 peptide-based and virus-like particle vaccine enhances the bioactivity of IL-17 in vitro and in vivo. Immunotherapy 2012; 4:1799 - 807; http://dx.doi.org/10.2217/imt.12.129; PMID: 23240747
   PubMed Web of Science ®Google Scholar
• Roseman AM, Borschukova O, Berriman JA, Wynne SA, Pumpens P, Crowther RA. Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies. J Mol Biol 2012; 423:63 - 78; http://dx.doi.org/10.1016/j.jmb.2012.06.032; PMID: 22750730
   PubMed Web of Science ®Google Scholar
• Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, Coyle AJ, Koike M, Spitalny GL, Kiener PA, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010; 125:1237 - 44, e2; http://dx.doi.org/10.1016/j.jaci.2010.04.005; PMID: 20513521
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011; 183:1007 - 14; http://dx.doi.org/10.1164/rccm.201008-1210OC; PMID: 21057005
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187:804 - 11; http://dx.doi.org/10.1164/rccm.201208-1414OC; PMID: 23471469
   PubMed Web of Science ®Google Scholar
• Doherty TA, Soroosh P, Khorram N, Fukuyama S, Rosenthal P, Cho JY, Norris PS, Choi H, Scheu S, Pfeffer K, et al. The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling. Nat Med 2011; 17:596 - 603; http://dx.doi.org/10.1038/nm.2356; PMID: 21499267
   PubMed Web of Science ®Google Scholar
• Hardyman MA, Wilkinson E, Martin E, Jayasekera NP, Blume C, Swindle EJ, Gozzard N, Holgate ST, Howarth PH, Davies DE, et al. TNF-α-mediated bronchial barrier disruption and regulation by src-family kinase activation. J Allergy Clin Immunol 2013; 132:665 - 75, e8; http://dx.doi.org/10.1016/j.jaci.2013.03.005; PMID: 23632299
   PubMed Web of Science ®Google Scholar
• Hansbro PM, Scott GV, Essilfie AT, Kim RY, Starkey MR, Nguyen DH, Allen PD, Kaiko GE, Yang M, Horvat JC, et al. Th2 cytokine antagonists: potential treatments for severe asthma. Expert Opin Investig Drugs 2013; 22:49 - 69; http://dx.doi.org/10.1517/13543784.2013.732997; PMID: 23126660
   PubMed Web of Science ®Google Scholar
• Ma Y, Guan Q, Bai A, Weiss CR, Hillman CL, Ma A, Zhou G, Qing G, Peng Z. Targeting TGF-beta1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis. Inflamm Bowel Dis 2010; 16:1040 - 50; http://dx.doi.org/10.1002/ibd.21167; PMID: 19924805
   PubMed Web of Science ®Google Scholar
• Ma Y, HayGlass KT, Becker AB, Fan Y, Yang X, Basu S, Srinivasan G, Simons FE, Halayko AJ, Peng Z. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med 2007; 176:439 - 45; http://dx.doi.org/10.1164/rccm.200610-1405OC; PMID: 17556715
   PubMed Web of Science ®Google Scholar
• Ma Y, Ma AG, Peng Z. A potential immunotherapy approach: mucosal immunization with an IL-13 peptide-based virus-like particle vaccine in a mouse asthma model. Vaccine 2007; 25:8091 - 9; http://dx.doi.org/10.1016/j.vaccine.2007.09.009; PMID: 17935839
   PubMed Web of Science ®Google Scholar
• Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov 2013; 12:117 - 29; http://dx.doi.org/10.1038/nrd3838; PMID: 23334207
   PubMed Web of Science ®Google Scholar
• Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 2013; 13:9 - 22; http://dx.doi.org/10.1038/nri3341; PMID: 23154224
   PubMed Web of Science ®Google Scholar
• Tachdjian R, Al Khatib S, Schwinglshackl A, Kim HS, Chen A, Blasioli J, Mathias C, Kim HY, Umetsu DT, Oettgen HC, et al. In vivo regulation of the allergic response by the IL-4 receptor alpha chain immunoreceptor tyrosine-based inhibitory motif. J Allergy Clin Immunol 2010; 125:1128 - 36, e8; http://dx.doi.org/10.1016/j.jaci.2010.01.054; PMID: 20392476
   PubMed Web of Science ®Google Scholar
• Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?. PLoS One 2008; 3:e3331; http://dx.doi.org/10.1371/journal.pone.0003331; PMID: 18836528
   PubMed Web of Science ®Google Scholar
• Enoksson M, Lyberg K, Möller-Westerberg C, Fallon PG, Nilsson G, Lunderius-Andersson C. Mast cells as sensors of cell injury through IL-33 recognition. J Immunol 2011; 186:2523 - 8; http://dx.doi.org/10.4049/jimmunol.1003383; PMID: 21239713
   PubMed Web of Science ®Google Scholar
• Enoksson M, Möller-Westerberg C, Wicher G, Fallon PG, Forsberg-Nilsson K, Lunderius-Andersson C, Nilsson G. Intraperitoneal influx of neutrophils in response to IL-33 is mast cell-dependent. Blood 2013; 121:530 - 6; http://dx.doi.org/10.1182/blood-2012-05-434209; PMID: 23093619
   PubMed Web of Science ®Google Scholar
• Alves-Filho JC, Sônego F, Souto FO, Freitas A, Verri WA Jr., Auxiliadora-Martins M, Basile-Filho A, McKenzie AN, Xu D, Cunha FQ, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 2010; 16:708 - 12; http://dx.doi.org/10.1038/nm.2156; PMID: 20473304
   PubMed Web of Science ®Google Scholar
• Guabiraba R, Besnard AG, Menezes GB, Secher T, Jabir MS, Amaral SS, Braun H, Lima-Junior RC, Ribeiro RA, Cunha FQ, et al. IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. Mucosal Immunol 2014; Forthcoming http://dx.doi.org/10.1038/mi.2013.124; PMID: 24424522
   PubMed Web of Science ®Google Scholar
• Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117:1538 - 49; http://dx.doi.org/10.1172/JCI30634; PMID: 17492053
   PubMed Web of Science ®Google Scholar
• Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009; 2:684 - 91; http://dx.doi.org/10.1161/CIRCHEARTFAILURE.109.873240; PMID: 19919994
   PubMed Web of Science ®Google Scholar
• Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB, Liew FY. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205:339 - 46; http://dx.doi.org/10.1084/jem.20071868; PMID: 18268038
   PubMed Web of Science ®Google Scholar
• Saidi S, Bouri F, Lencel P, Duplomb L, Baud’huin M, Delplace S, Leterme D, Miellot F, Heymann D, Hardouin P, et al. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine 2011; 53:347 - 54; http://dx.doi.org/10.1016/j.cyto.2010.11.021; PMID: 21190867
   PubMed Web of Science ®Google Scholar
• Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun 2009; 384:105 - 9; http://dx.doi.org/10.1016/j.bbrc.2009.04.081; PMID: 19393621
   PubMed Web of Science ®Google Scholar
• Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, Xu D, Sattar N, McInnes IB, Liew FY. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res 2010; 107:650 - 8; http://dx.doi.org/10.1161/CIRCRESAHA.110.218867; PMID: 20634488
   PubMed Web of Science ®Google Scholar
• Link A, Bachmann MF. Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines. Immunotherapy 2010; 2:561 - 74; http://dx.doi.org/10.2217/imt.10.30; PMID: 20636009
   PubMed Web of Science ®Google Scholar
• Le Buanec H, Bensussan A, Bagot M, Gallo RC, Zagury D. Active and passive anticytokine immune therapies: current status and development. Adv Immunol 2012; 115:187 - 227; http://dx.doi.org/10.1016/B978-0-12-394299-9.00007-2; PMID: 22608260
   PubMed Web of Science ®Google Scholar
• Jennings GT, Bachmann MF. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 2009; 49:303 - 26; http://dx.doi.org/10.1146/annurev-pharmtox-061008-103129; PMID: 18851703
   PubMed Web of Science ®Google Scholar